Cenexi turnaround delays
Cenexi's operational issues and capacity constraints may delay profitability, with management acknowledging a few quarters delay.
GLAND / Q4-FY24 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Pricing pressure in US generics
While pricing has stabilized, any resurgence of price erosion could impact base business margins.
Slow progress in biologics and China
Biologics CDMO and China market progress have been slower than anticipated, with no near-term material contribution expected.